Unraveling the Complex Relationship Between Autoimmune Diseases and Second Breast Cancers

Researchers at the Netherlands Cancer Institute, led by Gordon Watt, have been awarded a prestigious European Research Council grant to investigate the interaction between autoimmune diseases and cancer treatments, with a focus on reducing the risk of developing second breast cancers. The study aims to leverage novel molecular approaches and link large cohorts of cancer survivors with medical data to better understand the complex relationships between autoimmune disease, cancer treatment, and the risk of a subsequent breast cancer. This research has the potential to impact over 12 million female cancer survivors in Europe, where one in five newly diagnosed cancers is a second or subsequent cancer often related to treatment of an earlier cancer.

Key Takeaways:

• Autoimmune diseases, such as lupus or rheumatoid arthritis, may reduce the risk of a first breast cancer, but their interaction with cancer treatment is not well understood.
• The research aims to study how autoimmune conditions interact with cancer treatments like chemotherapy and influence the risk of developing a second breast cancer.
• Previous studies have shown that systemic autoimmune diseases may interact with cancer treatment in influencing the risk of treatment-related second breast cancer.
• The project has the potential to improve risk prediction, guide personalized follow-up care, and protect survivors from developing second cancers.
• Personalized follow-up care may become more effective due to a better understanding of the interaction between autoimmune diseases and cancer treatments.
• The study has the potential to reveal key insights into how the immune system influences cancer survivors' risk for new cancers.
• The findings could ultimately improve risk prediction and help protect survivors from developing second cancers.
• Gordie Watt's preliminary research suggests that autoimmune diseases may interact with cancer treatment in influencing the risk of treatment-related second breast cancer.
• The study will combine large population studies, advanced genetic analysis, and innovative statistical models to capture a wider range of autoimmune-like disease.
• The team will map how and when autoimmune disease develops and how it impacts the development of a second breast cancer.
• The study aims to develop new tools to capture a wider range of autoimmune-like disease, including subclinical forms that may be missed in clinical care.
• The research has the potential to reveal key insights into the interaction between autoimmune diseases and cancer treatments.
• The European Research Council awards grants to promising researchers, and the ERC Starting Grant is intended for talented scientists who show potential to become research leaders in their fields.
• The Netherlands Cancer Institute is among the world's best comprehensive cancer centers, combining innovative fundamental, translational, and clinical research with dedicated patient care.
• The research institute gratefully acknowledges funding from the Dutch Ministry of Health, Welfare and Sport, the Dutch Cancer Society, and individual donors.

Statistics:

• Over 12 million female cancer survivors in Europe are at risk for second breast cancers.
• One in five newly diagnosed cancers is a second or subsequent cancer often related to treatment of an earlier cancer.
• Second breast cancers are the most common, and tend to have fewer treatment options and worse outcomes than first breast cancers.

Sources:

• Netherlands Cancer Institute, "Researcher awarded grant to study relationship between cancer and autoimmune disease"
• European Research Council, "ERC Starting Grant"
• Netherlands Cancer Institute, "About us"